Denosumab discontinuation in non-metastatic breast cancer treated with AI raises vertebral fracture risk
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen production, AIs accelerate bone ...
Feb 10, 2026
0
6









